-
1
-
-
65449135642
-
Levodopa: Past, present, and future
-
Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1-8.
-
(2009)
Eur Neurol
, vol.62
, pp. 1-8
-
-
Hauser, R.A.1
-
2
-
-
65449189759
-
Optimizing levodopa therapy
-
Abbruzzese G. Optimizing levodopa therapy. Neurol Sci 2008;29:S377-9.
-
(2008)
Neurol Sci
, vol.29
-
-
Abbruzzese, G.1
-
3
-
-
57349093766
-
Levodopa for the treatment of Parkinson's disease
-
LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-76.
-
(2008)
N Engl J Med
, vol.359
, pp. 2468-2476
-
-
LeWitt, P.A.1
-
4
-
-
66949117423
-
The scientific and clinical basis for the treatment of Parkinson disease
-
Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(Suppl. 4):S1-136.
-
(2009)
Neurology
, vol.72
, Issue.SUPPL. 4
-
-
Olanow, C.W.1
Stern, M.B.2
Sethi, K.3
-
5
-
-
58149120928
-
L-Dopa therapy for Parkinson's disease: Past, present, and future
-
Nagatsu T, Sawada M. L-Dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 2009;15(Suppl. 1):S3-8.
-
(2009)
Parkinsonism Relat Disord
, vol.15
, Issue.SUPPL. 1
-
-
Nagatsu, T.1
Sawada, M.2
-
6
-
-
58149141585
-
Levodopa therapeutics for Parkinson's disease: New developments
-
LeWitt PA. Levodopa therapeutics for Parkinson's disease: new developments. Parkinsonism Relat Disord 2009;15(Suppl. 1):S31-4.
-
(2009)
Parkinsonism Relat Disord
, vol.15
, Issue.SUPPL. 1
-
-
LeWitt, P.A.1
-
7
-
-
0026526135
-
Levodopa: Pharmacology, pharmacokinetics, and pharmacodynamics
-
Juncos JL. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics. Neurol Clin 1992;10:487-509.
-
(1992)
Neurol Clin
, vol.10
, pp. 487-509
-
-
Juncos, J.L.1
-
8
-
-
58149180322
-
Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease
-
Nomoto M, Nishikawa N, Nagai M, et al. Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl. 1):S21-4.
-
(2009)
Parkinsonism Relat Disord
, vol.15
, Issue.SUPPL. 1
-
-
Nomoto, M.1
Nishikawa, N.2
Nagai, M.3
-
9
-
-
0028262953
-
Dietary factors in the management of Parkinson's disease
-
Kempster PA, Wahlqvist ML. Dietary factors in the management of Parkinson's disease. Nutr Rev 1994;52:51-8. (Pubitemid 24090161)
-
(1994)
Nutrition Reviews
, vol.52
, Issue.2 I
, pp. 51-58
-
-
Kempster, P.A.1
Wahlqvist, M.L.2
-
10
-
-
0037243824
-
Effects of food on the pharmacokinetics of levodopa in a dual-release formulation
-
DOI 10.1016/S0939-6411(02)00124-8
-
Crevoisier C, Zerr P, Calvi-Gries F, et al. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Eur J Pharm Biopharm 2003;55:71-6. (Pubitemid 36120497)
-
(2003)
European Journal of Pharmaceutics and Biopharmaceutics
, vol.55
, Issue.1
, pp. 71-76
-
-
Crevoisier, C.1
Zerr, P.2
Calvi-Gries, F.3
Nilsen, T.4
-
11
-
-
34948908635
-
The pharmacokinetics and pharmacodynamics of Levodopa in the treatment of Parkinson's disease
-
DOI 10.2174/157488407781668802
-
Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007;2:234-43. (Pubitemid 47520962)
-
(2007)
Current Clinical Pharmacology
, vol.2
, Issue.3
, pp. 234-243
-
-
Khor, S.-P.1
Hsu, A.2
-
12
-
-
0025869874
-
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease
-
Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-9.
-
(1991)
Ann Neurol
, vol.29
, pp. 556-559
-
-
Olanow, C.W.1
Gauger, L.L.2
Cedarbaum, J.M.3
-
13
-
-
50049087567
-
Molecular mechanisms of L-dopa-induced dyskinesia
-
Jenner P. Molecular mechanisms of L-dopa-induced dyskinesia. Nat Rev Neurosci 2008;9:665-77.
-
(2008)
Nat Rev Neurosci
, vol.9
, pp. 665-677
-
-
Jenner, P.1
-
14
-
-
0037407662
-
L-DOPA, dyskinesia and striatal plasticity
-
DOI 10.1038/nn0503-437
-
Dunnett S. L-dopa, dyskinesia and striatal plasticity. Nat Neurosci 2003;6:437-8. (Pubitemid 36514685)
-
(2003)
Nature Neuroscience
, vol.6
, Issue.5
, pp. 437-438
-
-
Dunnett, S.1
-
16
-
-
78049400764
-
Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption
-
Wang CL, Fan Y, Lu HH, et aL Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. J Biomed Sci 2010;17:71.
-
(2010)
J Biomed Sci
, vol.17
, pp. 71
-
-
Wang, C.L.1
Fan, Y.2
Lu, H.H.3
-
18
-
-
0027449341
-
Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats
-
DOI 10.1016/0006-8993(93)90576-9
-
Hudson JL, van Home CG, Stromberg I, et al. Correlation of apomorphine and amphetamine induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993;626:167-74. (Pubitemid 23306825)
-
(1993)
Brain Research
, vol.626
, Issue.1-2
, pp. 167-174
-
-
Hudson, J.L.1
Van Horne, C.G.2
Stromberg, I.3
Brock, S.4
Clayton, J.5
Masserano, J.6
Hoffer, B.J.7
Gerhardt, G.A.8
-
19
-
-
19444370500
-
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice
-
DOI 10.1016/j.bbr.2005.02.023, PII S0166432805000707
-
Iancu R, Mohapel P, Brundin P, et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162:1-10. (Pubitemid 40726275)
-
(2005)
Behavioural Brain Research
, vol.162
, Issue.1
, pp. 1-10
-
-
Iancu, R.1
Mohapel, P.2
Brundin, P.3
Paul, G.4
-
20
-
-
0035344211
-
Experimental models of Parkinson's disease
-
Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001;2:325-34.
-
(2001)
Nat Rev Neurosci
, vol.2
, pp. 325-334
-
-
Beal, M.F.1
-
21
-
-
34548819330
-
The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease
-
DOI 10.1016/j.parkreldis.2007.06.005, PII S1353802007001071
-
Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl. 1):S13-7. (Pubitemid 47444538)
-
(2007)
Parkinsonism and Related Disorders
, vol.13
, Issue.SUPPL. SEPT.
-
-
Nyholm, D.1
-
22
-
-
33746105694
-
Continuous dopamine-receptor treatment of Parkinson's disease: Scientific rationale and clinical implications
-
DOI 10.1016/S1474-4422(06)70521-X, PII S147444220670521X
-
Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006,5:677-87. (Pubitemid 44081890)
-
(2006)
Lancet Neurology
, vol.5
, Issue.8
, pp. 677-687
-
-
Olanow, C.W.1
Obeso, J.A.2
Stocchi, F.3
-
23
-
-
69749091694
-
Levodopa delivery systems for the treatment of Parkinson's disease: An overview
-
Goole J, Amighi K. Levodopa delivery systems for the treatment of Parkinson's disease: an overview. Int J Pharm 2009;380:1-15.
-
(2009)
Int J Pharm
, vol.380
, pp. 1-15
-
-
Goole, J.1
Amighi, K.2
|